Barcelona, Spain and El Segundo, California – Nov 18
ACCEPTED ABSTRACTS INCLUDE:
Spain PRO-WAVE1 study, conducted with eight hospitals, “PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform” (presents on November 18)
UK feasibility study, conducted with Health Innovation Oxford & Thames Valley, “Enhancing Prostate Cancer Management with Wave Health (Digital Health Platform): A feasibility study” (presents on November 20)
Barcelona, Spain and El Segundo, California – Treatment Technologies & Insights, Inc. (TTI) parent company of the Wave Health digital health platform, today announced that ISPOR, the professional society for health economics and outcomes research, has accepted two study abstracts that positively assessed the Wave Health tool designed to help both patients and care teams. A globally recognized digital health solution, (1) Wave Health activates patient engagement, compliance and personalized supported self-management while streamlining care workflows for treatment teams through automated communication and novel remote monitoring.
The Spain PRO-WAVE1 real world evidence study demonstrated a rare 93% patient compliance (despite a majority of participants being of older age, lower education, and low-tech confidence), alongside a 98% HCP perceived usefulness. Additionally, after completing the study, 78% of patients also responded to an optional feedback survey regarding their experience using Wave Health as a tool for tracking and managing their health during treatment. Those patients conveyed remarkable experiences, including: 90% reporting being satisfied with the app to track their activities and keep their medical team informed; and 95% describing the information provided by Wave Health as “useful” for their treatment journey.
The UK feasibility study was conducted to better understand NHS unmet clinical needs, with a specific focus on the prostate cancer (PC) pathway and ways to improve patient-centered care to impact short and long-term patient management.
The results showcased NHS stakeholders positively reviewing Wave Health to impact cancer management. Notably, the majority agreed the platform had the potential to support clinical decision making, improve patient management, reduce administrative workflow, and achieve costs savings.
TTI CEO Matt Lashey said: “We are honored to have multiple studies recognized at ISPOR and excited to be proving out the opportunity to alleviate healthcare capacity burdens and associated care costs while improving patient health literacy, quality of life and outcomes.” Lashey added, “The innovation is especially critical given expanding patient populations and soaring infrastructure burdens. The opportunity is to transform clinics with a trusted, scalable platform to support large volume patient populations – by remotely managing individual treatments based on local hospital needs and care team requirements.”
Spain Study Background – Full study abstract (Poster board #C025) is available here.
In the “PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform” study, patients engaged with the Wave Health App over a 13-week period. Patients used the app during treatment to complete a series of validated ePRO questionnaires, as well as a Weekly Symptom Review (WSR) assessing 16 Prostate cancer-specific symptoms, including the severity and/or frequency of each symptom. A report summary of the patients’ WSR was generated for care team to view in Wave Connect, a web-based platform – specifically for care team members to conduct weekly check-ins on patients, including verifying patient completion, evaluating report content, indicating plans for follow up with each patient, and rating their perceived value of the platform.
Dr. Ignacio Durán, the study primary investigator, based at Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, commented, “This study demonstrates that the platform is very relevant for patients. It is designed to give them an extra layer of care that very likely will translate into better quality of life and potentially longer survival.”
Dr. Estefania Linares, a lead investigator at the Hospital Universitario La Paz, added: “The platform is very practical and would benefit overpopulated hospitals, rural hospitals, and tele-consultations. It is maybe the most useful in departments where you’re not able to see patients frequently because of distance or the overload of patients.”
Hospital participants in the PRO-WAVE1 study included: Hospital Universitario Marques de Valdecilla; Complejo Hospitalario de Navarra; Oncológico de Donostia; Fundació Puigvert Barcelona; Hospital Universitario La Paz; Hospital Universitario Virgen del Rocío; Hospital de la Sta. Creu i Sant Pau; and Hospital Universitarios Cruces.
UK Study Background – Full study abstract (Poster board #MSR208) is available here.
*The Wave Health product has been created by TTI. In the UK, Bayer has partnered with TTI as marketing agent for the prostate cancer version of Wave Health in the UK and is not responsible for the content or function of the product in any way.
The “Enhancing Prostate Cancer Management with Wave Health (Digital Health Platform): A feasibility study” was undertaken by Health Innovation Oxford & Thames Valley and funded by Bayer Plc. The study used the Lean Assessment Process (LAP) methodology to assess the feasibility and barriers associated with adopting Wave Health to harness electronic patient-reported outcomes (ePROs) to support patient self-management and enable care team remote monitoring and risk stratification. Fifteen end-users from 7 NHS trusts, all who routinely make treatment and management decisions within the PC pathway, were interviewed and the study focused on understanding the potential benefits and acceptance for adoption by the NHS, with clinical pathway mapping related to prostate cancer management post-diagnosis.
James Rose, Director of Strategic and Industry Partnerships, Health Innovation Oxford & Thames Valley, said, “Our study indicates Wave Health could add substantial value to the current service and care pathway. We are excited to support the next phase of this work, where we hope to evaluate Wave Health in a real-world setting to further assess its impact on patients, the workforce, service outcomes, and health economics.”
About Health Innovation Oxford and Thames Valley
Health Innovation Oxford and Thames Valley (formerly the Oxford Academic Health Science Network) works with the NHS, research and industry to identify, develop and spread innovation that will benefit patients, populations, services and economies. Email: info@healthinnovationoxford.org / Web: www.healthinnovationoxford.org
About ISPOR Conference
The Professional Society for Health Economics and Outcomes Research global nonprofit is centered on improving healthcare decisions. The ISPOR Europe 2024 conference, themed “Generating Evidence Toward Health and Well-Being,” will be held 17 – 20 November in Barcelona, Spain. The conference program centers on the importance of scientific evidence in understanding and improving the health and well-being of people across the globe. Sessions will focus on the science, practice, and policies of healthcare value assessment and promote a broader view of health economics and outcomes research (HEOR) that considers the physical, mental, and social health aspects of innovation.
About Wave Health
Born from a personal cancer experience, Wave Health is a trusted, comprehensive digital health platform to transform the management and understanding of chronic conditions of large volume patient populations. Comprised of patient app and care portal, the platform efficiently collects, manages, and analyses missing patient reported data from outside the clinical setting (real-time and over the course of treatment). The platform generates actionable insights to drive patient engagement and adherence, and to help medical teams manage individual treatments including identifying emerging risks. For more information, please visit www.wavehealth.app.
1 Immunowave Study (Fred Hutchinson) – two abstract acceptances at ASCO 2023; PRO-WAVE1 Study (Spain) – poster presentation at ASCO GU 2024, abstract acceptance at ASCO 2024, poster presentation at ASCO Breakthrough 2024
Lu, DJ, et al. “Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review.” Adv Radiat Oncol. Jan-Feb. 2021.
Vercell, Amy, et al. “Patient-Facing Cancer Mobile Apps That Enable Patient Reported Outcome Data to Be Collected” International Journal of Medical Informatics, 25 Nov. 2022.
